Generic SSRIs and Dosing for Depression
For treating major depressive disorder in adults, start with escitalopram 10-20 mg daily, sertraline 50 mg daily, citalopram 20-40 mg daily, fluoxetine 20 mg daily, or paroxetine 20 mg daily—these lower-to-mid range doses provide optimal efficacy while minimizing side effects. 1
Recommended SSRIs and Starting Doses
The American College of Physicians guidelines 2 establish second-generation antidepressants (SGAs), particularly SSRIs, as first-line pharmacologic treatment for major depressive disorder. The most commonly prescribed generic SSRIs with their optimal dosing are:
Specific SSRI Dosing Recommendations
- Escitalopram: 10-20 mg daily (most effective SSRI based on response, remission, and tolerability) 3
- Sertraline: 50 mg daily initially
- Citalopram: 20-40 mg daily
- Fluoxetine: 20 mg daily (reference standard; 20-40 mg fluoxetine equivalents represents optimal range) 1
- Paroxetine: 20 mg daily
- Fluvoxamine: Standard dosing applies
Critical Dosing Principles
The lower-to-middle range of licensed doses achieves the best balance between efficacy, tolerability, and acceptability. 1 A comprehensive dose-response meta-analysis of 77 studies with 19,364 participants demonstrated that:
- SSRI efficacy increases gradually up to 20-40 mg fluoxetine equivalents, then plateaus or decreases at higher doses 1
- Dropout rates due to adverse effects increase steeply at higher doses 1
- The optimal therapeutic ceiling occurs around 250 mg imipramine equivalents (approximately 50 mg fluoxetine equivalent) 4
Key Advantage Over Older Antidepressants
Unlike tricyclic antidepressants that require gradual dose titration over weeks, SSRIs can be started at therapeutically effective doses immediately 5. This eliminates prolonged time to response and reduces early treatment discontinuation.
Important Caveats
Initial anxiety and delayed therapeutic effect: SSRIs commonly induce anxiety during the first 1-2 weeks of treatment before therapeutic benefits emerge at 6-12 weeks 6. Warn patients about this timeline to prevent premature discontinuation.
Common side effects to monitor:
- Sexual dysfunction (very common, dose-related)
- Sleep disturbance
- Nausea (typically transient)
- Initial anxiety/agitation 6
Modest efficacy limitations: SSRIs show limited effectiveness for anhedonia and cognitive impairment symptoms 6. If these symptoms predominate, consider alternative agents.
Pharmacogenetic Considerations
CYP2D6 and CYP2C19 polymorphisms significantly affect SSRI metabolism 7. For patients who are:
- Poor metabolizers: Start at lower doses to avoid toxicity
- Ultra-rapid metabolizers: May require higher doses for efficacy
This particularly affects paroxetine, fluvoxamine, and citalopram metabolism.
Treatment Duration
The acute treatment phase lasts 6-12 weeks, continuation phase 4-9 months, and maintenance phase ≥1 year for preventing recurrence 2. Response is defined as ≥50% reduction in depression severity.